Innovative Medicine has decided to halt the development of its epilepsy drug, three months after a Phase II trial with the drug failed to meet its endpoints. The therapy was developed in partnership ...
Pharmaceutical Technology
15 minutes ago
View all
addextherapeutics.com
Stock price: ADXN (NasdaqCM) $8.12 -0.02 (-0.31%)
Tue, Jul 23, 2024, 11:11AM EDT